{"id":99252,"date":"2024-01-12T17:00:28","date_gmt":"2024-01-12T17:00:28","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=99252"},"modified":"2024-01-11T12:44:01","modified_gmt":"2024-01-11T12:44:01","slug":"perseus-trial-results-daratumumab-vrd-in-newly-diagnosed-multiple-myeloma-ash-2023-pieter-sonneveld","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/haematological-malignancies\/conference-hub\/perseus-trial-results-daratumumab-vrd-in-newly-diagnosed-multiple-myeloma-ash-2023-pieter-sonneveld\/","title":{"rendered":"PERSEUS trial results: Daratumumab + VRd in newly diagnosed multiple myeloma: ASH 2023, Pieter Sonneveld"},"content":{"rendered":"
The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. In this interview\u00a0Prof. Pieter Sonneveld<\/strong>\u00a0(Erasmus MC Cancer Institute, Rotterdam, Netherlands) kindly joins us to discuss the current treatment landscape for NDMM and the role of autologous stem cell transplantation; the PERSUEUS trial rationale, design and key findings, highlighting potential implications of the results for the future treatment of NDMM.<\/p>\n The abstract entitled \u201cPhase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial<\/a>\u201d was presented at the\u00a065th ASH Annual Meeting and Exposition\u00a0<\/a>December 9-12, 2023, in San Diego, CA, USA.<\/p>\n Questions:<\/strong><\/p>\n Disclosures:\u00a0<\/strong>Pieter Sonneveld has nothing to disclose in relation to this interview.<\/p>\n Support:<\/strong>\u00a0Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.<\/p>\n\n